Mortality in patients with schizophrenia

The Lancet

Volumn 374, Issue 9701, 2009, Pages 1591-

  De Hert, M ^a   Peuskens, J ^a   van Winkel, R ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Department of Psychiatry and Psychology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

CAUSE OF DEATH; CIGARETTE SMOKING; DIABETES MELLITUS; DYSLIPIDEMIA; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; HYPERTENSION; LETTER; MEDICAL CARE; METABOLIC SYNDROME X; MORTALITY; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SURVIVAL; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; FOLLOW UP; METHODOLOGY; NOTE;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FOLLOW-UP STUDIES; HUMANS; RESEARCH DESIGN; RISK FACTORS; SCHIZOPHRENIA;

EID: 70350589308     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61942-5     Document Type: Letter

References (5)

1. Tiihonen J., Lönnqvist J., Wahlbeck K., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374 (2009) 620-627
2. Palmer B.A., Pankratz V.S., and Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62 (2005) 247-253
3. Weinmann S., Read J., and Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113 (2009) 1-11
4. Joukamaa M., Heliövaara M., Knekt P., Aromaa A., Raitasalo R., and Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188 (2006) 122-127
5. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., and King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 64 (2007) 242-249